Microsoft word - m-asprevarelease-040309-f.doc

1:00 PM EST; Tuesday March 9, 2004

Aspreva Pharmaceuticals Completes First-Round Private Equity Financing,
Raising US$57 million
Victoria, B.C., Canada; March 9, 2004 - Aspreva Pharmaceuticals Corporation, creators of a unique pharmaceutical asset partnering model, today announced the completion of a $57 million (Cdn$76 million) private equity financing. Sprout Group, one of the oldest and largest US institutional venture capital firms and an affiliate of Credit Suisse First Boston, led the investment with significant participation from InterWest Partners, a large diversified venture capital firm. Other investors in the international syndicate included HBM Partners, Thomas Weisel Healthcare Ventures, BioAsia Investments LLC and Axiom Venture Partners. This financing, one of the largest series A financings reported in North America, consists of $53 million in venture capital funds and $4.2 million in converted debt. Aspreva’s initial core therapeutic area of focus is autoimmunity, and the company will use these proceeds to initiate and fund clinical trials in several autoimmune diseases with CellCept® (mycophenolate mofetil), its first licensed therapeutic. In addition it will grow the business through further product partnerships. The company will expand the number of core therapeutic franchises based upon future strategic alliances utilizing its novel asset partnering model. In October 2003, Aspreva announced a major partnership with F. Hoffmann-La Roche, in which Aspreva acquired the worldwide rights (excluding Japan) to develop and commercialize Roche's transplant medication CellCept for all autoimmune indications. CellCept is currently the leading branded transplant medication in the United States and holds tremendous promise for the treatment of autoimmune diseases. Clinical research, including a significant study reported in the March 4, 2004 issue of the New England Journal of Medicine1, has demonstrated the potential value of CellCept over the current standard of care in the treatment of lupus nephritis. Richard Glickman, Chairman and CEO commented, “We are pleased to be working with investors of this caliber. They have the depth of experience and understanding of the pharmaceutical industry that will make them significant contributors as Aspreva executes its business plan and undergoes a phase of rapid growth. In the next twelve months, with multiple phase III trials on-going, with operations on three continents and with CellCept, one of the most promising new autoimmune disease treatments, Aspreva will emerge as a major force in the autoimmune disease arena.” "Aspreva's ability to attract such leading investors is further confirmation of the relevance of our business model. The unique Aspreva asset partnering approach unlocks a whole new paradigm for the pharmaceutical industry, addressing the need to maximize the value of existing product assets while maintaining core market focus. The significance of this financing also speaks to the growing excitement around the emerging role of CellCept in autoimmune diseases such as lupus, for which there has been no new approved medication for more than 30 years," said Noel Hall, President and Co-Founder of Aspreva. 1 Contreras et al, Sequential Therapies for Proliferative Lupus Nephritis, NEJM 2004 Vol 350:971-980.
Ron Hunt, Partner at Sprout Group, commented, "We made a significant investment in Aspreva based on
the company's seasoned leadership, visionary approach to drug commercialization and tremendous asset
in CellCept. From our perspective, Aspreva's deal with Roche is one of the best licensing agreements
recently forged in the industry. By investing in additional clinical development and commercialization
programs that significantly enhance the value of this key Roche brand, this licensing deal enables
Aspreva to establish a powerful commercial autoimmune disease franchise. We believe that CellCept has
the potential to become the new standard of care in the treatment of a number of key autoimmune
diseases that affect millions of patients in North America alone.”
Mr. Hunt will be joining Aspreva's Board of Directors, as will Dr Arnold Oronsky general partner of
InterWest Partners. Mr. Hunt has over 18 years of experience in the pharmaceutical industry working as a
venture capitalist, a pharmaceutical consultant and in the commercial operations of SmithKline Beecham
and Johnson & Johnson. Dr Oronsky has 30 years experience in the pharmaceutical industry, previously
holding positions as Vice President, Research, Lederle Laboratories and Head of Immunology Research,
Ciba-Geigy Pharmaceuticals.
BMO Nesbitt Burns and Harris Nesbitt, the investment and corporate banking arms of BMO Financial
Group, served as financial advisor and private placement agent for Aspreva.
About Aspreva Pharmaceuticals
Aspreva's novel business model, based on asset partnering, is revolutionizing pharmaceutical partnering
and bringing desperately needed evidence-based medicines to underserved patient populations. Aspreva
enables its pharmaceutical partners to undertake label expansion for existing products, achieving
incremental revenue and enhancing both pharmaceutical and corporate brand value.
Aspreva Pharmaceuticals identifies, develops and commercializes new applications for existing
medicines. The medicines we choose to develop are anticipated to have high therapeutic value for
underserved diseases. We define 'underserved' as those populations for which there is currently a lack of
adequate treatment options and few if any treatments in development. This encompasses less common
and neglected diseases.
The pharmaceutical industry understands the needs within these underserved markets, but has
traditionally been challenged in addressing them due to the highly specialized nature of these conditions,
and the fiscal and structural restraints that necessitate a focus on more prevalent diseases.
Aspreva’s innovative approach, along with our expertise in the clinical development and
commercialization of therapies for underserved diseases, establishes Aspreva as the pharmaceutical
industry's "partner of choice" for therapeutic product expansion. It is the strength of our partnerships that
ultimately ensures real benefit to patients. For more information please visit our website at:
About Sprout Group

Founded in 1969, Sprout Group is one of the oldest and largest venture capital firms in the United States.
Sprout has helped finance more than 300 companies with combined sales exceeding $40 billion and
currently manages approximately $2 billion in committed capital. With offices in Menlo Park and New
York, Sprout focuses on helping to grow promising companies at all stages of development in the
healthcare technology and information technology sectors. Sprout's healthcare team is actively investing
in medical devices, biopharmaceuticals, and laboratory technologies and services. Representative recent
healthcare technology investments include: Adolor, Aspreva, Corixa, Epicor, Focus Technologies, ISTA
Pharmaceuticals, Kalypsys, Sirna Therapeutics, Spiration, TolerRx, and Visiogen. Sprout Group is a
venture capital affiliate of Credit Suisse First Boston. For further information on the Sprout Group, please
visit their web site at
For more information contact:

Sandra MacPherson, Aspreva Pharmaceuticals 250-744-2488


Qalivere , Josese March 26, 2008 Josese Qalivere, 62, of Lahaina, a waiter, died at home. He was born in Fiji. He is survived by wife Likusiani "Liku"; sons Emori, Sonny and Libert; stepsons John and Foley Tukana; daughters Reapi Kaina, Sivoki, Vani and Vevila; stepdaughter Cecilia Tukana; brothers Vatimi Tatukivei; sisters Latileta and Lavinia; and 22 grandchildren. Services: 11

Microsoft word - i080117.doc

I n f o r m a t i o n s m a t e r i a l v o m 1 7 . 0 1 . 2 0 0 8 Zysten, Fisteln und Co. Der 18. November 1686 war der aufregendste Tag im Leben des Chirurgen Charles- François Félix (1653-1703). Ein Jahr lang hatte sich sein Patient der von ihm vorge- schlagenen Operation seiner Analfistel verweigert. Nun reckte er ihm den After ent- gegen, bereit, einige schmerzhafte Schnitte zu ertragen,

Copyright © 2010 Find Medical Article